Showing results (211-220 of 267) with videos related to

Sort By:
Pageof 27
Haematologica|August 12, 2021
Renal function and clinical outcome of patients with cancer-associated venous thromboembolism randomized to receive apixaban or dalteparin. Results from the Caravaggio trialCecilia Becattini, Rupert Bauersachs, Giorgio Maraziti, et al.
The American Journal of Medicine|December 18, 2016
Outcome of Patients with Venous Thromboembolism and Factor V Leiden or Prothrombin 20210 Carrier Mutations During the Course of AnticoagulationInna Tzoran, Manolis Papadakis, Benjamin Brenner, et al.
European Journal of Cancer (Oxford, England : 1990)|March 2, 2022
Recurrent venous thromboembolism and major bleeding in patients with localised, locally advanced or metastatic cancer: an analysis of the Caravaggio studyMelina Verso, Giancarlo Agnelli, Andrés Munoz, et al.
Leukemia Research|January 22, 2005
Meeting report. Acute promyelocytic leukemia-associated coagulopathy, 21 January 2004, London, United KingdomMartin S Tallman, Benjamin Brenner, Javier de la Serna, et al.
Nanophotonics (Berlin, Germany)|July 25, 2022
Monolithic dual-wedge prism-based spectroscopic single-molecule localization microscopyKi-Hee Song, Benjamin Brenner, Wei-Hong Yeo, et al.
Thrombosis Research|March 7, 2017
Gender-related differences in the outcome of patients with venous thromboembolism and thrombophiliaInna Tzoran, Emmanouil Papadakis, Benjamin Brenner, et al.
Biochimica Et Biophysica Acta. Molecular Cell Research|October 2, 2017
Grb2 regulates the proliferation of hematopoietic stem and progenitors cellsCatherine Frelin, Yishai Ofran, Julie Ruston, et al.
Chest|November 6, 2016
Development of a Risk Prediction Score for Occult Cancer in Patients With VTELuis Jara-Palomares, Remedios Otero, David Jimenez, et al.
The New England Journal of Medicine|September 24, 2010
Fondaparinux for the treatment of superficial-vein thrombosis in the legsHervé Decousus, Paolo Prandoni, Patrick Mismetti, et al.
Thrombosis and Haemostasis|March 27, 2004
IGIV-C, a novel intravenous immunoglobulin: evaluation of safety, efficacy, mechanisms of action, and impact on quality of lifeJames B Bussel, Amiram Eldor, John G Kelton, et al.
Pageof 27